Lecanemab clinical trials
Also written BAN2401.
How each study uses lecanemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lecanemab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Jan 2023 · LEQEMBI · BLA 761269 (FDA, Drugs@FDA)
- European Union
- 15 Apr 2025 · Leqembi · EMEA/H/C/005966 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 6
Eisai Inc. (5) · Washington University School of Medicine (2) · Ali Rezai (1) · Eisai Co., Ltd. (1) · Yonsei University (1) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1) · First Affiliated Hospital of Wenzhou Medical University (1)
Often tested with
Tested in the same studies.
Gantenerumab (1) · Solanezumab (1) · Etalanetug (1) · Aducanumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test lecanemab, phase 3 first.
- Dec 2026A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseasePhase 3 · Eisai Inc.
Studies
Open first, then newest update. How each study uses lecanemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's BiomarkersRecruitingPhase 4The Fourth Affiliated Hospital of Zhejiang University School of MedicineNCT07688460Written as Lecanemab
- Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics ApproachsRecruitingPhase 4First Affiliated Hospital of Wenzhou Medical UniversityNCT07604896Written as Lecanemab 10 mg/kg
- Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD PathologyNot yet recruitingNot applicableYonsei UniversityNCT07544953Written as Lecanemab
- A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseActive, not recruitingPhase 3Eisai Inc.NCT03887455Written as Lecanemab IV
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's DiseaseActive, not recruitingPhase 3Washington University School of MedicineNCT06384573Written as lecanemab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Active, not recruitingPhase 2/3Washington University School of MedicineNCT01760005Written as Lecanemab
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidActive, not recruitingPhase 3Eisai Inc.NCT04468659Written as Lecanemab
- A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseCompletedPhase 2Eisai Inc.NCT01767311Written as Lecanemab 2.5 mg/kg
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) TherapyActive, not recruitingEarly Phase 1Ali RezaiNCT05469009Written as Lecanemab
- A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy ParticipantsCompletedPhase 1Eisai Inc.NCT05533801Written as Lecanemab
- A Study of Subcutaneous Lecanemab in Healthy ParticipantsCompletedPhase 1Eisai Inc.NCT05045716Written as Lecanemab
- A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseCompletedPhase 1Eisai Co., Ltd.NCT02094729Written as BAN2401 2.5 mg/kg
Given beside what is tested · 4 — lecanemab is usual care or a partner of the new treatment
- The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.Not yet recruitingPhase 2Neurology Office of South FloridaNCT07212062Written as Lecanemab 10 mg/kg
- Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)RecruitingPhase 3Zhejiang Provincial People's HospitalNCT06530732Written as Lecanemab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)Active, not recruitingPhase 2/3Washington University School of MedicineNCT05269394Written as Lecanemab
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseActive, not recruitingPhase 2Eisai Inc.NCT06602258Written as Lecanemab
As the comparator · 1 — what is tested is compared with lecanemab
Codes
What other systems call lecanemab · ClinicalTrials.gg INT000561
- MeSH (NLM) C000612089lecanemabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 12PYH0FTU9LECANEMABConfirmed FDA, NLM, Wikidata
- Wikidata Q56274769lecanemabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175105LecanemabOne source FDA
- DrugBank DB14580One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000612089 | lecanemab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 12PYH0FTU9 | LECANEMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q56274769 | lecanemab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175105 | Lecanemab | One source FDA |
| DrugBank | DB14580 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.